Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 employs a sustained-release drug-delivery platform for intravesical administration.
|
$124.14M |
$3.75
-1.45%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$121.11M |
$0.39
-8.44%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$118.89M |
$0.72
-2.17%
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$117.16M |
$13.72
+4.97%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$113.69M |
$36.15
-2.97%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$113.31M |
$5.66
-2.08%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$110.83M |
$2.59
+0.78%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$110.69M |
$3.73
+7.04%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$109.15M |
$1.76
-4.35%
|
|
MGNX
MacroGenics, Inc.
Pipeline includes antibody-drug conjugates (MGC026, MGC028, vobra duo) using a TOP1i payload.
|
$108.71M |
$1.72
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$107.96M |
$4.38
-1.91%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$107.84M |
$1.54
-1.28%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$107.27M |
$1.47
+6.16%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$106.43M |
$3.35
-8.83%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$105.00M |
$3.21
-0.47%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
RCEL
AVITA Medical, Inc.
RECELL/autologous cell suspension represents a cell-therapy platform within regenerative medicine.
|
$103.81M |
$3.91
+13.01%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$103.60M |
$2.02
-2.18%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$103.50M |
$2.75
+7.42%
|
|
XGN
Exagen Inc.
Exagen's biomarker-based tests (e.g., AVISE CTD, SLE T-cell markers, RA33) align with companion diagnostics.
|
$103.20M |
$4.69
-2.90%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$102.45M |
$1.81
-15.58%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$101.96M |
$8.36
+2.33%
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$101.82M |
$0.64
-4.64%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$99.90M |
$1.41
+1.08%
|
|
CSBR
Champions Oncology, Inc.
Core oncology focus via PDX TumorBank and data assets.
|
$99.41M |
$7.17
+0.03%
|
Showing page 16 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
